Autolus Therapeutics (AUTL) AI Stock Analysis

• Market Cap: $455.10M
• Dividend Yield: N/A
• Average Volume (3M): 1.52M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.30
• Revenue Growth: 407.86%
• EPS Growth: 30.35%
• Country: US
• Employees: 647
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.30
• Shares Outstanding: 266,143,280
• 10 Day Avg. Volume: 1,762,524
• 30 Day Avg. Volume: 1,520,832
• PEG Ratio: 0.10
• Price to Book (P/B): 1.40
• Price to Sales (P/S): 59.25
• P/FCF Ratio: -2.49
• Enterprise Value/Market Cap: 0.96
• Enterprise Value/Revenue: 8.50
• Enterprise Value/Gross Profit: -2.75
• Enterprise Value/Ebitda: -1.73
• 1Y Price Target: $8.00
• Price Target Upside: 367.84% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): -0.81
• Revenue Forecast (FY): $135.99M

• Rating: 51 Neutral
• Price Target: $1.50 ▼(-12.28% Downside)
• Action: Upgraded Date: 01/27/26
• Date: Action: Upgraded 01/27/26

The score is held back primarily by weak financial performance (large operating losses and substantial cash burn) and soft technicals (below major moving averages with negative MACD). Offsetting these, the latest earnings update reflects meaningful early commercialization progress and operational milestones, supporting a mid-range score despite valuation being difficult to assess due to negative earnings.

Positive Factors

Commercial launch traction and manufacturing reliability

Sustained commercial adoption across 60 centers with >90% manufacturing success and patient coverage indicates durable operational capability and clinician acceptance. This foundation supports repeatable revenue, network effects in referral patterns, and scale benefits as volumes expand into new indications.

Secured long-term lentiviral supply

A decade-long lentiviral supply agreement locks in a critical input for CAR-T manufacturing, reducing supply-chain risk and enabling multi-year capacity planning. Predictable vector availability supports scale, margin improvement initiatives, and mitigates a key operational bottleneck for durable commercialization.

Near-term cash runway visibility

Management’s projection that existing cash can fund operations into Q4 2027 provides a multi-quarter runway to execute commercialization, optimize manufacturing, and advance pivotal trials. This reduces immediate refinancing pressure and allows focus on operational improvements and strategic investments.

Negative Factors

Heavy negative operating cash flow

Sustained negative operating and free cash flow at this scale signifies ongoing cash burn that will require financing unless offset by faster revenue growth or cost reductions. Persistent cash outflows constrain strategic flexibility, increase dilution risk, and pressure timing for achieving self-funding operations.

Large operating losses and negative margins

Deep operating losses and negative gross profit underscore that the business remains far from break-even. Long-term shareholder value depends on converting commercial traction into positive unit economics; until margins turn positive, returns on equity will remain negative and equity value can be eroded.

Current unit economics: cost of sales > revenue

Manufacturing and cost structure currently produce negative gross margins, meaning each unit sold destroys value. Sustainable commercialization requires technological or process-driven cost cuts, pricing adjustments, or scale efficiencies; otherwise expansion into new indications will worsen cash burn.

Autolus Therapeutics Business Overview & Revenue Model

Company Description

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.

How the Company Makes Money

Autolus Therapeutics generates revenue primarily through strategic partnerships and collaborations with larger pharmaceutical companies, which provide funding for research and development activities in exchange for rights to commercialize products developed from Autolus' technology. Additionally, the company may receive milestone payments as its product candidates progress through clinical trials and regulatory approvals. While Autolus is primarily in the development phase and may not yet have substantial product sales, revenue can also be derived from licensing agreements and grants to support its ongoing research initiatives.

Autolus Therapeutics Financial Statement Overview

Summary

Revenue growth is strong (TTM +70.8%), but the business remains far from profitable with deeply negative gross profit and large operating losses (TTM EBIT -$439.5M; net loss -$224.8M). Cash burn is heavy (TTM operating cash flow -$254.2M; free cash flow -$278.0M), implying ongoing dependence on external capital despite manageable leverage (debt-to-equity ~0.19).

Income Statement

TTM (Trailing-Twelve-Months) revenue accelerated sharply (+70.8%), showing improving scale, but profitability remains very weak. Gross profit is deeply negative and operating losses are large (EBIT -$439.5M; net loss -$224.8M), with very negative margins, indicating the business is still heavily investment-driven and far from break-even despite the revenue ramp.

Balance Sheet

Leverage looks manageable in TTM (Trailing-Twelve-Months), with relatively low debt versus equity (debt-to-equity ~0.19) and a sizable equity base ($265.5M) against total assets ($661.9M). The key weakness is persistent negative returns on equity (TTM ROE ~-56%), meaning losses are still eroding value and the balance sheet strength depends on continued funding discipline.

Cash Flow

Cash generation is a clear pressure point: TTM (Trailing-Twelve-Months) operating cash flow is -$254.2M and free cash flow is -$278.0M, with free cash flow worsening year over year (about -10.9%). While free cash flow is broadly in line with the net loss (suggesting losses are not purely accounting-driven), the ongoing cash burn implies continued reliance on external capital until profitability improves.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	51.13M	10.12M	1.70M	6.19M	1.51M	1.72M
Gross Profit	-158.22M	-130.90M	1.70M	6.19M	1.51M	-133.17M
EBITDA	-250.91M	-233.07M	-156.77M	-132.24M	-132.47M	-162.58M
Net Income	-224.80M	-220.66M	-208.38M	-148.84M	-142.10M	-142.09M
Balance Sheet
Total Assets	661.95M	782.73M	375.38M	490.27M	405.56M	294.24M
Cash, Cash Equivalents and Short-Term Investments	367.41M	588.02M	239.57M	382.44M	310.34M	154.09M
Total Debt	65.83M	52.63M	52.97M	24.26M	68.01M	54.16M
Total Liabilities	396.50M	355.40M	263.91M	191.60M	92.24M	84.20M
Stockholders Equity	265.45M	427.32M	111.47M	298.67M	313.32M	210.03M
Cash Flow
Free Cash Flow	-278.04M	-241.09M	-156.57M	-123.15M	-126.72M	-132.44M
Operating Cash Flow	-254.18M	-206.27M	-145.59M	-112.31M	-117.86M	-117.76M
Investing Cash Flow	-311.67M	-394.55M	-10.99M	-10.84M	-8.86M	-14.68M
Financing Cash Flow	27.46M	589.55M	-883.00K	223.61M	284.06M	74.42M

Autolus Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.71
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AUTL, the sentiment is Positive. The current price of 1.71 is above the 20-day moving average (MA) of 1.53, above the 50-day MA of 1.59, and below the 200-day MA of 1.74, indicating a neutral trend. The MACD of 0.07 indicates Negative momentum. The RSI at 59.64 is Neutral, neither overbought nor oversold. The STOCH value of 66.10 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AUTL.

Autolus Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CTNM	54 Neutral	$560.36M	-6.80	-30.40%	―	―	-100.71%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AUTL	51 Neutral	$455.10M	-2.03	-60.52%	―	407.86%	30.35%
BNTC	49 Neutral	$374.46M	-11.73	-29.59%	―	―	80.95%
DMAC	49 Neutral	$414.02M	-11.08	-64.12%	―	―	-29.73%
TVRD	46 Neutral	$37.43M	-0.40	-97.61%	―	-53.67%	86.75%
LRMR	45 Neutral	$454.48M	―	-78.24%	―	―	-67.41%

Autolus Therapeutics Corporate Events

Autolus Therapeutics Signs Long-Term Lentiviral Supply Agreement

On January 21, 2026, Autolus Limited, a subsidiary of Autolus Therapeutics, entered into a new ten-year Master Service Agreement with AGC Biologics S.p.A. for the manufacture and supply of lentiviral vectors, replacing a prior arrangement between the parties. The non-exclusive agreement sets out general commercial and regulatory terms and commits Autolus to purchase a minimum of 14 batches of lentiviral vector in the first two calendar years and at least EUR 25 million of products and services over the following five-year period, while giving AGC a first right to negotiate for new manufacturing activities related to Autolus’s obe-cel product, thereby securing a key component of Autolus’s CAR-T manufacturing supply chain and reinforcing long-term operational planning for its lead therapy.

The most recent analyst rating on (AUTL) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Autolus Therapeutics stock, see the AUTL Stock Forecast page.

Autolus issues 2025 AUCATZYL results and 2026 outlook

On January 12, 2026, Autolus reported preliminary unaudited net product revenue from AUCATZYL of about $24 million for the fourth quarter of 2025 and approximately $75 million for full-year 2025, the first year of commercial sales, supported by a US launch across more than 60 treatment centers and initial approvals in the UK and EU. The company issued 2026 AUCATZYL revenue guidance of $120 million to $135 million, highlighted real-world data from the ROCCA consortium confirming strong efficacy and a favorable safety profile, and outlined a strategy to drive top-line growth, turn gross margin positive through manufacturing efficiencies, and extend obe-cel into pediatric B-ALL, lupus nephritis, progressive multiple sclerosis and AL amyloidosis, while indicating its current cash resources should fund operations into the fourth quarter of 2027, though all 2025 figures remain preliminary and subject to audit adjustments.

The most recent analyst rating on (AUTL) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Autolus Therapeutics stock, see the AUTL Stock Forecast page.

Autolus Therapeutics Appoints Ryan Richardson to Board

On December 1, 2025, Autolus Therapeutics announced the appointment of Ryan Richardson as a Class I director on its Board of Directors. Mr. Richardson, who has over 20 years of experience in healthcare and investment banking, previously served as Chief Strategy Officer at BioNTech SE, where he played a significant role in the company’s global expansion and transition to a commercial stage. His expertise is expected to aid Autolus in its growth as a commercial-stage company, particularly in expanding the reach of its therapy, obe-cel, in new indications.

The most recent analyst rating on (AUTL) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Autolus Therapeutics stock, see the AUTL Stock Forecast page.

Autolus Therapeutics Appoints New Principal Accounting Officer

On November 7, 2025, Autolus Therapeutics announced the resignation of Rob Dolski as Principal Accounting Officer, with Patrick McIlvenny appointed to the role effective the same day. The company reported third-quarter 2025 financial results, including $21.1 million in net product revenue for AUCATZYL® and 60 authorized treatment centers. Autolus is advancing its obe-cel therapy for pediatric r/r B-ALL and severe lupus nephritis, with promising clinical data and FDA designations supporting further trials. Leadership changes aim to bolster commercial growth and operational efficiency.

The most recent analyst rating on (AUTL) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Autolus Therapeutics stock, see the AUTL Stock Forecast page.